Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells

Silvia M. Sirchia, Anne T. Ferguson, Elena Sironi, Smitha Subramanyan, Rosaria Orlandi, Saraswati Sukumar, Nicoletta Sacchi

Research output: Contribution to journalArticle

Abstract

Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor β, RARβ, gene expression. Search of the causes affecting RARβ gene activity has been oriented at identifying possible differences either at the level of one of the RARβ promoters, RARβ2, or at regulatory factors. We hypothesized that loss of RARβ2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RARβ2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RARβ2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RARβ2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RARβ2 and expression of RARβ indicating that DNA methylation is at least one factor, contributing to RARβ inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RARβ2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RARβ2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RARβ transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RARβ activity, and help to overcome the hurdle of RA-resistance in breast cancer.

Original languageEnglish (US)
Pages (from-to)1556-1563
Number of pages8
JournalOncogene
Volume19
Issue number12
StatePublished - Mar 16 2000

Fingerprint

Retinoic Acid Receptors
Tretinoin
Epigenomics
Chromatin
Breast Neoplasms
decitabine
trichostatin A
Cell Line
Histone Deacetylase Inhibitors
Chromatin Assembly and Disassembly
Methyltransferases
DNA Methylation
Methylation
Gene Expression
Polymerase Chain Reaction
DNA
Pharmaceutical Preparations
Genes

Keywords

  • Breast cancer
  • Chromatin remodeling
  • DNA methylation
  • Retinoic acid receptor (RAR) β

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Sirchia, S. M., Ferguson, A. T., Sironi, E., Subramanyan, S., Orlandi, R., Sukumar, S., & Sacchi, N. (2000). Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 19(12), 1556-1563.

Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. / Sirchia, Silvia M.; Ferguson, Anne T.; Sironi, Elena; Subramanyan, Smitha; Orlandi, Rosaria; Sukumar, Saraswati; Sacchi, Nicoletta.

In: Oncogene, Vol. 19, No. 12, 16.03.2000, p. 1556-1563.

Research output: Contribution to journalArticle

Sirchia, SM, Ferguson, AT, Sironi, E, Subramanyan, S, Orlandi, R, Sukumar, S & Sacchi, N 2000, 'Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells', Oncogene, vol. 19, no. 12, pp. 1556-1563.
Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene. 2000 Mar 16;19(12):1556-1563.
Sirchia, Silvia M. ; Ferguson, Anne T. ; Sironi, Elena ; Subramanyan, Smitha ; Orlandi, Rosaria ; Sukumar, Saraswati ; Sacchi, Nicoletta. / Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. In: Oncogene. 2000 ; Vol. 19, No. 12. pp. 1556-1563.
@article{55304c97a0624e1fa85e3485ddb92f18,
title = "Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells",
abstract = "Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor β, RARβ, gene expression. Search of the causes affecting RARβ gene activity has been oriented at identifying possible differences either at the level of one of the RARβ promoters, RARβ2, or at regulatory factors. We hypothesized that loss of RARβ2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RARβ2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RARβ2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RARβ2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RARβ2 and expression of RARβ indicating that DNA methylation is at least one factor, contributing to RARβ inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RARβ2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RARβ2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RARβ transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RARβ activity, and help to overcome the hurdle of RA-resistance in breast cancer.",
keywords = "Breast cancer, Chromatin remodeling, DNA methylation, Retinoic acid receptor (RAR) β",
author = "Sirchia, {Silvia M.} and Ferguson, {Anne T.} and Elena Sironi and Smitha Subramanyan and Rosaria Orlandi and Saraswati Sukumar and Nicoletta Sacchi",
year = "2000",
month = "3",
day = "16",
language = "English (US)",
volume = "19",
pages = "1556--1563",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells

AU - Sirchia, Silvia M.

AU - Ferguson, Anne T.

AU - Sironi, Elena

AU - Subramanyan, Smitha

AU - Orlandi, Rosaria

AU - Sukumar, Saraswati

AU - Sacchi, Nicoletta

PY - 2000/3/16

Y1 - 2000/3/16

N2 - Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor β, RARβ, gene expression. Search of the causes affecting RARβ gene activity has been oriented at identifying possible differences either at the level of one of the RARβ promoters, RARβ2, or at regulatory factors. We hypothesized that loss of RARβ2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RARβ2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RARβ2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RARβ2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RARβ2 and expression of RARβ indicating that DNA methylation is at least one factor, contributing to RARβ inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RARβ2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RARβ2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RARβ transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RARβ activity, and help to overcome the hurdle of RA-resistance in breast cancer.

AB - Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor β, RARβ, gene expression. Search of the causes affecting RARβ gene activity has been oriented at identifying possible differences either at the level of one of the RARβ promoters, RARβ2, or at regulatory factors. We hypothesized that loss of RARβ2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RARβ2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RARβ2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RARβ2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RARβ2 and expression of RARβ indicating that DNA methylation is at least one factor, contributing to RARβ inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RARβ2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RARβ2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RARβ transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RARβ activity, and help to overcome the hurdle of RA-resistance in breast cancer.

KW - Breast cancer

KW - Chromatin remodeling

KW - DNA methylation

KW - Retinoic acid receptor (RAR) β

UR - http://www.scopus.com/inward/record.url?scp=0034673671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034673671&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 1556

EP - 1563

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 12

ER -